Latest News for: nsclc

Edit

Non-Small Cell Lung Cancer (NSCLC) - Market Insights, Epidemiology, and Forecast - 2036 | 7MM ...

Nasdaq Globe Newswire 07 Oct 2026
.
Edit

ArriVent Announces Program Update from the Phase 3 FURVENT Trial of Firmonertinib in First-Line EGFR Exon 20 Insertion Mutant NSCLC (Form 8-K) (ArriVent Biopharma Inc)

Public Technologies 06 Oct 2026
ArriVent Announces Program Update from the Phase 3 FURVENT Trial of Firmonertinib in First-Line EGFR Exon 20 Insertion Mutant NSCLC ... About EGFR mutant NSCLC ... Mutational activation of the EGFR is a frequent and early event in the development of NSCLC.
Edit

New Drug Application Submission Initiated for Zipalertinib Plus Chemotherapy in First-Line EGFR Exon 20 Insertion Mutation NSCLC for Review Under FDA Real-Time Oncology Review Program (Form 8-K) (Cullinan Therapeutics Inc)

Public Technologies 02 Oct 2026
New Drug Application Submission Initiated for Zipalertinib Plus Chemotherapy in First-Line EGFR Exon 20 Insertion Mutation NSCLC for Review Under FDA Real-Time Oncology Review Program ... exon20ins NSCLC.
Edit

Flatiron Health Expands Global Panoramic Datasets With AI-Powered Breast Cancer and NSCLC Real-World Data for ...

Business Wire 29 Sep 2026
... Cancer and Non-Small Cell Lung Cancer (NSCLC) Panoramic datasets in the UK, Germany, and Japan.
Edit

BeyondSpring Announces FDA Fast Track Designation for Plinabulin in Post-ICI Non-Squamous NSCLC and Strategic Transaction ...

Nasdaq Globe Newswire 29 Sep 2026
Food and Drug Administration (“FDA”) has granted Fast Track designation to Plinabulin and docetaxel for the treatment of patients with advanced or ...
Edit

New study evaluates a medication for NSCLC with the KRAS G12C mutation (Providence Health & Services)

Public Technologies 29 Sep 2026
This is an abstract of the document. To keep reading, click here and get access to the original version. Attachments Original document Permalink.
Edit

BeyondSpring Announces FDA Fast Track Designation for Plinabulin in Post-ICI Non-Squamous NSCLC and Strategic Transaction to Advance Global Phase 3 DUBLIN-4 Trial Toward Planned Interim Analysis (Form 8-K) (BeyondSpring Inc)

Public Technologies 29 Sep 2026
Its differentiated immuno-modulating mechanism and previously reported encouraging clinical data from DUBLIN-3 and Study 303 support the trial design of DUBLIN-4 in Plinabulin mechanism-targeted post-ICI non-squamous NSCLC patients.
Edit

Innovent Announces Expansion of Global Phase 3 MarsLight-11 Study of IBI363/TAK-928 (Alpha-biased IL-2/PD-1 Bispecific Fusion Protein) in Immunotherapy-Resistant NSCLC to Include Patients with Non-Squamous NSCLC (Innovent Biologics Inc)

Public Technologies 28 Sep 2026
). The text version of this document is not available ... Disclaimer ... (noodl. 134739283) .
Edit

Innovent Announces Expansion of Global Phase 3 MarsLight-11 Study of IBI363/TAK-928 (Alpha-biased IL-2/PD-1 Bispecific Fusion Protein) in Immunotherapy-Resistant NSCLC to Include Patients with Non-Squamous NSCLC

PR Newswire 28 Sep 2026
TAK-928) in patients with squamous non-small cell lung cancer (NSCLC) whose disease has progressed on or after chemotherapy and immunotherapy, to include patients with non-squamous NSCLC ... NSCLC.
Edit

Ivonescimab-Chemo Versus Placebo-Chemo in EGFR-TKI–Resistant, EGFR-Mutated NSCLC (HARMONi): Updated Overall Survival Analysis (Summit Therapeutics Inc)

Public Technologies 15 Sep 2026
). The text version of this document is not available ... Attachments Permalink. Disclaimer.
Edit

Overall Survival Analysis From HARMONi-2: Ivonescimab vs Pembrolizumab as First-line Treatment for PD-L1-Positive NSCLC (Summit Therapeutics Inc)

Public Technologies 15 Sep 2026
). The text version of this document is not available ... Attachments Permalink. Disclaimer.
Edit

Presentation follows receipt of FDA Fast Track designation for BH-30643 for the treatment of advanced or metastatic EGFR C797S-positive NSCLC (Form 8-K) (Blossomhill Therapeutics Inc)

Public Technologies 15 Sep 2026
advanced or metastatic EGFR C797S-positive NSCLC ... inhibitors for the treatment of EGFR-mutant NSCLC ... BlossomHill plans to initiate a global Phase 2 study targeting EGFR C797S-positive NSCLC in Q1 2027.
Edit

WCLC 2026 | HANSOH PHARMA ANNOUNCES PROFFERED ORAL PRESENTATION OF PHASE I STUDY DATA OF HS-10370 COMBINED WITH ADEBRELIMAB AND CHEMOTHERAPY IN ADVANCED KRAS G12C-MUTATED NSCLC (Hansoh Pharmaceutical Group Co Ltd)

Public Technologies 14 Sep 2026
HANSOH PHARMA ANNOUNCES PROFFERED ORAL PRESENTATION OF PHASE I STUDY DATA OF HS-10370 COMBINED WITH ADEBRELIMAB AND CHEMOTHERAPY IN ADVANCED KRAS G12C-MUTATED NSCLC ... About KRAS G12C-mutated NSCLC.
Edit

Kelun-Biotech Announces Phase III Study of Sacituzumab Tirumotecan (sac-TMT) in Combination with Pembrolizumab as First-Line Treatment for PD-L1-Negative Non-Squamous NSCLC Met Primary Endpoint

PR Newswire 15 Jul 2026
This is the world's first Phase III clinical study of an ADC combined with an immune checkpoint inhibitor to meet its primary endpoint in the first-line treatment of driver gene‑negative and PD‑L1‑negative non-squamous NSCLC.
Edit

Amivantamab Lazertinib Forecast to Lead US EGFR NSCLC Therapy Revenue by 2036 as Post-TAGRISSO Competition Intensifies

Nasdaq Globe Newswire 14 Jul 2026
.

Article Search

tools
×
×
×
×